Literature DB >> 33170158

Genetic analysis of genes associated with epilepsy.

Giulia Guerri1, Marco Castori2, Leonardo D'Agruma3, Antonio Petracca4, Danjela Kurti5, Matteo Bertelli6.   

Abstract

BACKGROUND AND AIM: Epilepsy is a neurological disorder in which the altered activity of neurons causes convulsions, periods of unusual behavior and, sometimes, loss of consciousness. The aim of this mini-review is to summarize all the syndromes characterized by epilepsy and for which the associated gene is known.
METHODS: We searched those syndromes in PubMed and OMIM database.
RESULTS: Genetic causes underlie epilepsy in about 40% of individuals. Epilepsies are phenotypically and genetically heterogeneous. Inheritance can be autosomal dominant or recessive or X-linked recessive/dominant.
CONCLUSION: Since epilepsy has high genetic heterogeneity, in diagnostics, the parallel sequencing of a panel of genes may speed up the determination of the molecular etiology and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures.

Entities:  

Year:  2020        PMID: 33170158      PMCID: PMC8023140          DOI: 10.23750/abm.v91i13-S.10596

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


Epilepsy is a neurological disorder in which the altered activity of neurons causes convulsions, periods of unusual behavior and, sometimes, loss of consciousness. The International League against Epilepsy (ILAE) classifies seizures in two main categories: “Idiopathic generalized epileptic seizures” involving both cerebral hemispheres and which can manifest with typical absences, myoclonus and generalized tonic-clonic seizures, alone or in various combinations and severity, and “Focal seizures” that arise in neural networks of a single hemisphere, and are in turn distinguished into simple partial seizures that do not involve an alteration of consciousness, and complex partial seizures that cause a change in behavior or loss of consciousness. Some types of seizures, such as infantile spasms, do not fall into either category (1). Epilepsy may be an isolated neurological symptom or may be associated with other neurological symptoms or diseases (2). Anti-convulsant drugs are the main treatment for epilepsy and often have to be taken throughout life (3). About 1% of the world’s population suffers from epilepsy (4). A diagnosis of epilepsy is based on clinical observation, family history and clinical investigations, such as electroencephalogram, computed tomography and magnetic resonance imaging (5). Syncope, hyperventilation, migraines, narcolepsy, panic attacks and non-epileptic psychogenic seizures can be confused with seizures. In children, some behaviors, such as emotional spasms, bed-wetting, night terrors, tics and myoclonus, can easily be mistaken for epileptic seizures; gastroesophageal reflux can cause arching of the back and sideways head twisting in infants, and this can be confused with tonic-clonic seizures (6). Genetic causes underlie epilepsy in about 40% of individuals (7). Epilepsies are phenotypically and genetically heterogeneous. Inheritance can be autosomal dominant or recessive or X-linked recessive or dominant (Table 1).
Table 1.

Syndromes characterized by epilepsy for which the genetic basis is known.

AD = Autosomal dominant; AR = Autosomal recessive; ADSLD = Adenyl succinase deficiency; AHC = Alternating hemiplegia of childhood; AS = Angelman syndrome; BFIS = Benign familial infantile seizures; BFNS = Benign familial neonatal seizures; CADEDS = Cerebellar atrophy, developmental delay, seizures; CCDS = Cerebral creatine deficiency syndrome; CLN = neuronal ceroid lipofuscinosis; DOORS = Deafness, onychodystrophy, osteodystrophy, mental retardation, seizures syndrome; EA = Episodic ataxia; EEOC = childhood-onset epileptic encephalopathy; EIEE = Early infantile epileptic encephalopathy; EKD = Episodic kinesigenic dyskinesia; ENFL = Nocturnal frontal lobe epilepsy; EPD = Pyridoxine-dependent epilepsy; EPM = Progressive myoclonic epilepsy; EPRPDC = Rolandic epilepsy with paroxysmal exercise-induced dystonia and writer’s cramp; ETL = Familial temporal lobe epilepsy; FCORD = Focal cortical dysplasia; FEB = Familial febrile seizures; FESD = Focal epilepsy with speech disorder with/without mental retardation; FHM = Familial hemiplegic migraine; FIME = Familial infantile myoclonic epilepsy; GEFSP = Generalized epilepsy with febrile seizures plus; GLUT1DS = GLUT1 deficiency syndrome; HPMRS = Hyperphosphatasia with mental retardation syndrome; ICCA = Familial infantile convulsions with paroxysmal choreoathetosis; KDVS = Koolen-De Vries syndrome; KLEFS = Kleefstra syndrome; MAE = Myoclonic-atonic epilepsy; MCAHS = Multiple congenital anomalies-hypotonia-seizures syndrome; MCSZ = Microcephaly, seizures, developmental delay; MEDS = Microcephaly, epilepsy, diabetes syndrome; MICPCH = Mental retardation and microcephaly with pontine and cerebellar hypoplasia; MOWS = Mowat-Wilson syndrome; MRD = Mental retardation; MRX = X-linked mental retardation; MRXSCH = Syndromic X-linked mental retardation, Christianson type; MRXSH = Syndromic X-linked mental retardation, Hedera type; MTDPS = Mitochondrial DNA depletion syndrome; MYOCL = Familial myoclonus; NDHMSD/R = autosomal dominant/recessive neurodevelopmental disorder with or without hyperkinetic movements and seizures; NEDCAS = Neurodevelopmental disorder with cerebellar atrophy with/without seizures; NBIA = Neurodegeneration with brain iron accumulation; PMSE = Polyhydramnios, megalencephaly, symptomatic epilepsy; PNKD = Paroxysmal nonkinesigenic dyskinesia with/without generalized epilepsy; PNPOD = Pyridoxamine 5-prime-phosphate oxidase deficiency; PTHS/L = Pitt-Hopkins syndrome/-like; PVNH = Periventricular nodular heterotopia; RESDX = X-linked Rolandic epilepsy, mental retardation, speech dyspraxia; RMFSL = Lethal neonatal rigidity and multifocal seizure syndrome; RTT = Rett syndrome; SANDO = Sensory ataxic neuropathy, dysarthria, ophthalmoparesis; SESAMES = Seizures, sensorineural deafness, ataxia, mental retardation, electrolyte imbalance; SMAPME = Spinal muscle atrophy with progressive myoclonic epilepsy; THMD = Thiamine metabolism dysfunction syndrome; XLD/R = X-linked, dominant/recessive.

GeneOMIM geneDiseaseOMIM diseaseInheritanceProtein function (https://www.genecards.org/)
ATP1A2182340AHC1, FHM2104290, 602481ADCatalytic subunit of the pump that maintains an essential electrochemical gradient in cells through active transport of Na+ and K+ ions
ATP1A3182350AHC2614820ADCatalytic subunit of the pump that maintains an essential electrochemical gradient in cells through active transport of Na+ and K+ ions
CACNA1A601011EIEE42617106ADMediation of Ca2+ influx in response to depolarization. Regulation of neurotransmission
CHD2602119EEOC615369ADChromatin remodeling
CHRNA2118502ENFL4610353ADAlpha subunit of the nicotinic acetylcholine receptor involved in fast synaptic transmission
CHRNA4118504ENFL1600513ADIntegral membrane receptor subunit of the nicotinic acetylcholine receptor
CHRNB2118507ENFL3605375ADBeta subunit of the neuronal acetylcholine receptor
CPA6609562ETL5, FEB11614417, 614418AD, ARProteolytic inactivation of enkephalins and neurotensin. Conversion of inactive angiotensin I into active angiotensin II
DNAJC5611203CLN4B162350ADCalcium-dependent neurotransmitter release at nerve endings
DNM1602377EIEE31616346ADVesicle trafficking and receptor-mediated endocytosis
DYRK1A600855MRD7614104ADRegulation of cell proliferation. Brain development
EHMT1607001KLEFS1610253ADG0/G1 cell cycle transition
FOXG1164874RTT613454ADEstablishment of regional subdivision of the developing brain and telencephalon development
GABRA1137160EIEE19615744ADFormation of functional GABAergic synapses, mediation of synaptic inhibition
GABRB3137192EIEE43617113ADFormation of functional GABAergic synapses, mediation of synaptic inhibition
GRIN1138249NDHMSD/R614254AD, ARPlasticity of synapses that underlies memory and learning
GRIN2A138253FESD245570ADHigher sensitivity of glutamate and faster NMDA channel kinetics
GRIN2B138252EIEE27616139ADBrain development, circuit formation, synaptic plasticity, cell migration and differentiation
HNRNPU602869EIEE54617391ADFormation of ribonucleoprotein complexes in the nucleus with heterogeneous nuclear RNA
KANSL1612452KDVS610443ADAcetylation of nucleosomal histone H4 on lysine residues involved in transcription regulation
KCNMA1600150PNKD3, CADEDS609446, 617643AD, ARControl of excitability for the regulation of smooth muscle contraction, tuning of cochlear hair cells, regulation of transmitter release, innate immunity
KCNA1176260EA1160120ADRegulation of neuron excitability in the hippocampus, downstream effector for G protein-coupled receptors, inhibition of GABAergic inputs to basolateral amygdala neurons, regulation of neurotransmitter release, generation of action potentials and prevention of hyperexcitability in myelinated axons of the vagus nerve
KCNQ2602235EIEE7, BFNS1613720, 121200ADRegulation of neuron excitability
KCNQ3602232BFNS2121201ADRegulation of neuron excitability
LGI1604619ETL1600512ADRegulation of voltage-gated potassium channel activity, neuron growth regulation, cell survival
MBD5611472MRD1156200ADHeterochromatin binding
MEF2C600662MRD20613443ADRole in hippocampal-dependent learning and memory through regulation of basal and evoked synaptic transmission. Normal neuron development and distribution, neocortical electrical activity
PRRT2614386ICCA, EKD1, BFIS2602066, 128200, 605751ADSynaptic transmission in the central nervous system Neurotransmitter release in presynaptic terminals of hippocampal neurons
SCN1A182389GEFSP2, EIEE6604403, 607208ADRegulation of neurotransmitter release
SCN2A182390EIEE11, BFIS3613721, 607745ADRegulation of hippocampal replay, important for memory
SCN8A600702MYOCL2, EIEE13, BFIS5618364, 614558, 617080ADIon pore region of voltage-gated sodium channel. Essential for rapid membrane depolarization during action potential formation in excitable neurons
SCN9A603415GEFSP7613863ADMediation of voltage-dependent sodium ion permeability of excitable membranes
SLC2A1138140GLUT1DS1/2606777, 612126AD, ARExpressed at the blood-brain barrier, facilitation of glucose transport into the brain
SLC6A1137165MAE616421ADGABA reuptake into presynaptic terminals
SPTAN1182810EIEE5613477ADCa2+-dependent interaction with calmodulin, Ca2+-dependent movement of the cytoskeleton at plasma membrane
STXBP1602926EIEE4612164ADRelease of neurotransmitters via regulation of syntaxin
SYNGAP1603384MRD5612621ADRegulation of synaptic plasticity and neuron homeostasis
TCF4602272PTHS610954ADInitiation of neuron differentiation
TSC1605284FCORD2607341AD (somatic)Negative regulation of anabolic cell growth
TSC2191092Tumor suppressor
MTOR601231Central regulator of cell metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals
ZEB2605802MOWS235730ADTranscriptional inhibitor. Represses transcription of E-cadherin
UBE3A601623AS105830ADRegulator of synaptic development
ABAT137150GABA-transaminase deficiency613163ARCatabolism of gamma-aminobutyric acid
ADSL608222ADSLD103050ARDe novo AMP synthesis
ALDH7A1107323EPD266100ARCatabolism of betaine aldehyde, lipid peroxidation-derived aldehydes, lysine
ASAH1613468SMAPME159950ARCatabolism of ceramide into sphingosine and free fatty acids
BRAT1614506NEDCAS, RMFSL618056, 614498ARRegulation of mitochondrial function and cell proliferation
CLN3607042CLN3204200ARMicrotubule-dependent, anterograde transport of late endosomes and lysosomes
CLN5608102CLN5256731ARRetrograde trafficking of lysosomal sorting
CLN6606725CLN4A, CLN6601780, 204300ARDegradation of post-translationally modified proteins in lysosomes
CLN8607837CLN8, neuronal ceroid lipofuscinosis 8 Northern epilepsy variant600143, 610003ARCell proliferation during neuronal differentiation and protection against cell death
CNTNAP2604569PTHSL1610042ARRadial and longitudinal organization of myelinated axons. Formation of functionally distinct domains critical for saltatory conduction of nerve impulses in myelinated nerve fibers. Demarcation of the juxtaparanodal region of the axo-glial junction
CSTB601145Myoclonic epilepsy of Unverricht and Lundborg254800ARProtection against proteases leaking from lysosomes
CTSD116840CLN10610127ARProtein turnover, and proteolytic activation of hormones and growth factors
EPM2A607566Myoclonic epilepsy of Lafora254780ARPrevention of formation of glycogen-insoluble aggregates
FOLR1136430Neurodegeneration due to cerebral folate transport deficiency613068ARRequired for normal embryo development and normal cell proliferation
GAMT601240CCDS2612736ARImportant in nervous system development
GATM602360CCDS3612718AREmbryo and central nervous system development
GOSR2604027EPM6614018ARTransport of proteins from the cis/medial-Golgi to the trans-Golgi network
IER3IP1609382MEDS614231ARRegulation of apoptosis. Involved in protein transport between endoplasmic reticulum and Golgi apparatus
KCNJ10602208SESAMES612780ARResponsible for potassium buffering action of glial cells in the brain
KCTD7611725EPM3611726ARControl of excitability of cortical neurons
MFSD8611124CLN7610951ARTransport of small solutes via chemiosmotic ion gradients
NHLRC1608072Myoclonic epilepsy of Lafora254780ARMisfolded protein degradation via the ubiquitin-proteasome system
PIGN606097MCAHS1614080ARGlycosylphosphatidylinositol-anchor biosynthesis
PIGO614730HPMRS2614749ARGlycosylphosphatidylinositol-anchor biosynthesis
PLCB1607120EIEE12613722ARSynthesis of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate
PNPO603287PNPOD610090ARCatalysis of the terminal rate-limiting step of vitamin B6 synthesis
POLG174763MTDPS4A/4B, SANDO203700, 613662, 607459ARReplication of mitochondrial DNA
PPT1600722CLN1256730ARCatabolism of lipid-modified proteins during lysosomal degradation
PRICKLE1608500EPM1B612437ARInvolved in the planar cell polarity pathway that controls convergent extension during gastrulation and neural tube closure
PNKP605610MCSZ613402ARRepair of DNA damage
SCARB2602257EPM4254900ARMembrane transport and reorganization of the endosomal/lysosomal compartment
SLC19A3606152THMD2607483ARHigh affinity thiamine uptake
SLC25A22609302EIEE3609304ARTransport of glutamate across the inner mitochondrial membrane
STRADA608626PMSE611087ARG1 cell cycle arrest
TBC1D24613577DOORS, EPRPDC, EIEE16, FIME220500, 608105, 615338, 605021ARNeuronal projection development
TPP1607998CLN2204500ARNon-specific lysosomal peptidase which generates tripeptides from lysosomal proteinase breakdown products
WWOX605131EIEE28616211ARTumor suppressor gene
ALG13300776EIEE36300884XLDProtein N-glycosylation
ARHGEF9300429EIEE8300607XLRReceptor recruitment in GABAergic and glycinergic synapses
ARX300382EIEE1308350XLRMaintenance of neuron subtypes in the cerebral cortex, axonal guidance in the floor plate
ATP6AP2300556MRXSH300423XLRControl of V-ATPase pump assembly and acidification of lysosomes. Role in synapse morphology, synaptic transmission
CASK300172MICPCH300749XLDRegulation of mitochondrial function and cell proliferation
CDKL5300203EIEE2300672XLRCiliogenesis
FLNA300017PVNH1300049XLDNeuroblast migration from ventricular zone into cortical plate. Ciliogenesis. Cell-cell contacts and adherens junctions during brain development. Required for growth cone collapse during axon guidance
IQSEC2300522MRX1309530XLDComponent of postsynaptic density at excitatory synapses. Critical role in cytoskeletal and synapse organization
MECP2300005RTT312750XLDEssential for embryo development
PCDH19300460EIEE9300086XL, female restrictedCa2+-dependent cell-adhesion protein primarily expressed in the brain
PIGA311770MCAHS2300868XLRNecessary for synthesis of N-acetylglucosaminyl-phosphatidylinositol, early intermediate in GPI-anchor biosynthesis
SLC6A8300036CCDS1300352XLRRequired for uptake of creatine by muscles and brain
SLC9A6300231MRXSCH300243XLDExchange of protons for Na+ and K+ across endosome membranes. Ca2+ homeostasis
SMC1A300040EIEE85301044XLDPart of functional kinetochores
SRPX2300642RESDX300643XLRPromotion of synapse formation
WDR45300526NBIA5300894XLDAutophagosome assembly
Syndromes characterized by epilepsy for which the genetic basis is known. AD = Autosomal dominant; AR = Autosomal recessive; ADSLD = Adenyl succinase deficiency; AHC = Alternating hemiplegia of childhood; AS = Angelman syndrome; BFIS = Benign familial infantile seizures; BFNS = Benign familial neonatal seizures; CADEDS = Cerebellar atrophy, developmental delay, seizures; CCDS = Cerebral creatine deficiency syndrome; CLN = neuronal ceroid lipofuscinosis; DOORS = Deafness, onychodystrophy, osteodystrophy, mental retardation, seizures syndrome; EA = Episodic ataxia; EEOC = childhood-onset epileptic encephalopathy; EIEE = Early infantile epileptic encephalopathy; EKD = Episodic kinesigenic dyskinesia; ENFL = Nocturnal frontal lobe epilepsy; EPD = Pyridoxine-dependent epilepsy; EPM = Progressive myoclonic epilepsy; EPRPDC = Rolandic epilepsy with paroxysmal exercise-induced dystonia and writer’s cramp; ETL = Familial temporal lobe epilepsy; FCORD = Focal cortical dysplasia; FEB = Familial febrile seizures; FESD = Focal epilepsy with speech disorder with/without mental retardation; FHM = Familial hemiplegic migraine; FIME = Familial infantile myoclonic epilepsy; GEFSP = Generalized epilepsy with febrile seizures plus; GLUT1DS = GLUT1 deficiency syndrome; HPMRS = Hyperphosphatasia with mental retardation syndrome; ICCA = Familial infantile convulsions with paroxysmal choreoathetosis; KDVS = Koolen-De Vries syndrome; KLEFS = Kleefstra syndrome; MAE = Myoclonic-atonic epilepsy; MCAHS = Multiple congenital anomalies-hypotonia-seizures syndrome; MCSZ = Microcephaly, seizures, developmental delay; MEDS = Microcephaly, epilepsy, diabetes syndrome; MICPCH = Mental retardation and microcephaly with pontine and cerebellar hypoplasia; MOWS = Mowat-Wilson syndrome; MRD = Mental retardation; MRX = X-linked mental retardation; MRXSCH = Syndromic X-linked mental retardation, Christianson type; MRXSH = Syndromic X-linked mental retardation, Hedera type; MTDPS = Mitochondrial DNA depletion syndrome; MYOCL = Familial myoclonus; NDHMSD/R = autosomal dominant/recessive neurodevelopmental disorder with or without hyperkinetic movements and seizures; NEDCAS = Neurodevelopmental disorder with cerebellar atrophy with/without seizures; NBIA = Neurodegeneration with brain iron accumulation; PMSE = Polyhydramnios, megalencephaly, symptomatic epilepsy; PNKD = Paroxysmal nonkinesigenic dyskinesia with/without generalized epilepsy; PNPOD = Pyridoxamine 5-prime-phosphate oxidase deficiency; PTHS/L = Pitt-Hopkins syndrome/-like; PVNH = Periventricular nodular heterotopia; RESDX = X-linked Rolandic epilepsy, mental retardation, speech dyspraxia; RMFSL = Lethal neonatal rigidity and multifocal seizure syndrome; RTT = Rett syndrome; SANDO = Sensory ataxic neuropathy, dysarthria, ophthalmoparesis; SESAMES = Seizures, sensorineural deafness, ataxia, mental retardation, electrolyte imbalance; SMAPME = Spinal muscle atrophy with progressive myoclonic epilepsy; THMD = Thiamine metabolism dysfunction syndrome; XLD/R = X-linked, dominant/recessive. Pathogenic variants may be missense, nonsense, splice-site and small intragenic deletions/insertions. The test guidelines can be found in “Genetics Home Reference” (ghr.nlm.nih.gov). The test is useful for confirming diagnosis, differential diagnosis and recurrence risk evaluation. The search for pathogenic variants in the genes listed in Table 1 is based on analysis of a multi-gene panel by next generation sequencing of the coding regions and their intron-exon junctions. The test has an analytic sensitivity of 96-100% and an analytic specificity of ≥99%, compared with a diagnostic sensitivity of ≥37% deduced from the literature (8,9). Since epilepsy has high genetic heterogeneity (10), the use in diagnostics of a large panel of genes may speed up the determination of the molecular etiology and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures.
  6 in total

1.  Standards for epidemiologic studies and surveillance of epilepsy.

Authors:  David J Thurman; Ettore Beghi; Charles E Begley; Anne T Berg; Jeffrey R Buchhalter; Ding Ding; Dale C Hesdorffer; W Allen Hauser; Lewis Kazis; Rosemarie Kobau; Barbara Kroner; David Labiner; Kore Liow; Giancarlo Logroscino; Marco T Medina; Charles R Newton; Karen Parko; Angelia Paschal; Pierre-Marie Preux; Josemir W Sander; Anbesaw Selassie; William Theodore; Torbjörn Tomson; Samuel Wiebe
Journal:  Epilepsia       Date:  2011-09       Impact factor: 5.864

2.  Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform.

Authors:  Erika Della Mina; Roberto Ciccone; Francesca Brustia; Baran Bayindir; Ivan Limongelli; Annalisa Vetro; Maria Iascone; Laura Pezzoli; Riccardo Bellazzi; Gianfranco Perotti; Valentina De Giorgis; Simona Lunghi; Giangennaro Coppola; Simona Orcesi; Pietro Merli; Salvatore Savasta; Pierangelo Veggiotti; Orsetta Zuffardi
Journal:  Eur J Hum Genet       Date:  2014-05-21       Impact factor: 4.246

3.  Diagnostic yield of clinical next-generation sequencing panels for epilepsy.

Authors:  Jason Wang; Garrett Gotway; Juan M Pascual; Jason Y Park
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

Review 4.  Developments in molecular genetic diagnostics: an update for the pediatric epilepsy specialist.

Authors:  Amanda W Pong; Deb K Pal; Wendy K Chung
Journal:  Pediatr Neurol       Date:  2011-05       Impact factor: 3.372

5.  Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.

Authors:  Anne T Berg; Samuel F Berkovic; Martin J Brodie; Jeffrey Buchhalter; J Helen Cross; Walter van Emde Boas; Jerome Engel; Jacqueline French; Tracy A Glauser; Gary W Mathern; Solomon L Moshé; Douglas Nordli; Perrine Plouin; Ingrid E Scheffer
Journal:  Epilepsia       Date:  2010-02-26       Impact factor: 5.864

Review 6.  The challenge of neuropsychiatric issues in pediatric epilepsy.

Authors:  John M Pellock
Journal:  J Child Neurol       Date:  2004-08       Impact factor: 1.987

  6 in total
  1 in total

Review 1.  Dogs as a Natural Animal Model of Epilepsy.

Authors:  Wolfgang Löscher
Journal:  Front Vet Sci       Date:  2022-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.